Lineage Cell Therapeutics, Inc.

Historical 13F Holders

Symbol
LCTX
CUSIP
53566P109
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 53566P109 since 12/18/2024, newest first.

Filer % of Class Filed
BlackRock, Inc. 13G 5.3% 7/29/2026
Event 6/30/2026
Broadwood Partners, L.P. 13D/A Amendment 29
23.1% 11/14/2025
Event 11/12/2025
Chernett Jorey 13G 5.0% 9/26/2025
Event 9/22/2025
BlackRock, Inc. 13G/A Amendment 1 1.0% 7/17/2025
Event 6/30/2025
BlackRock, Inc. 13G 5.0% 4/24/2025
Event 3/31/2025
BlackRock, Inc. 13G/A Amendment 1 4.6% 2/5/2025
Event 12/31/2024
Broadwood Partners, L.P. 13D/A Amendment 28
24.5% 1/28/2025
Event 1/27/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 26 7.96 M $7.61 M
2026 Q2 135 117 M $155 M
2026 Q1 134 112 M $177 M
2025 Q4 128 102 M $170 M
2025 Q3 118 87.9 M $149 M
2025 Q2 134 98.0 M $88.6 M
2025 Q1 131 109 M $49.7 M
2024 Q4 130 107 M $53.8 M
2024 Q3 118 95.2 M $86.2 M
2024 Q2 119 100 M $100 M
2024 Q1 121 95.0 M $141 M
2023 Q4 121 77.0 M $83.9 M
2023 Q3 107 75.5 M $89.1 M
2023 Q2 110 75.6 M $107 M
2023 Q1 120 69.8 M $105 M
2022 Q4 110 65.6 M $76.7 M
2022 Q3 106 64.7 M $73.1 M
2022 Q2 103 65.0 M $103 M
2022 Q1 115 72.9 M $112 M
2021 Q4 135 74.5 M $182 M
2021 Q3 122 75.8 M $192 M
2021 Q2 123 73.1 M $209 M
2021 Q1 110 60.3 M $142 M
2020 Q4 99 55.3 M $97.4 M
2020 Q3 78 53.6 M $50.2 M
2020 Q2 98 55.7 M $48.5 M
2020 Q1 101 63.9 M $52.9 M
2019 Q4 110 64.9 M $57.8 M
2019 Q3 100 65.6 M $64.3 M
2019 Q2 1 18.0 k $20.0 k